Cargando…

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

Detalles Bibliográficos
Autores principales:	Gillmore, Julian D, Falk, Rodney H, Maurer, Mathew S, Hanna, Mazen, Karsten, Verena, Vest, John, Gollob, Jared, Hawkins, Philip N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641992/ http://dx.doi.org/10.1186/1750-1172-10-S1-O21

Ejemplares similares

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Analysis of disease progression in patients with transthyretin cardiac amyloidosis
por: Gilmore, Julian D, et al.
Publicado: (2015)

Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis
por: Zanazzi, George, et al.
Publicado: (2019)

DISCOVERY: a study examining the prevalence of transthyretin mutations in subjects suspected of having cardiac amyloidosis
por: Akinboboye, Olakunle, et al.
Publicado: (2015)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
por: Sutherland, Jessica E., et al.
Publicado: (2020)

Wild-type transthyretin amyloidosis in female patients
por: Kristen, Arnt V, et al.
Publicado: (2015)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis
por: Butler, James S., et al.
Publicado: (2016)

Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study
por: Cortese, Andrea, et al.
Publicado: (2015)

Liver‐directed drugs for transthyretin‐mediated amyloidosis
por: Brannagan, Thomas H., et al.
Publicado: (2022)

RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Empirical use of anakinra in AA amyloidosis of uncertain aetiology
por: Lane, T, et al.
Publicado: (2015)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Mitra-clip in Transthyretin Amyloidosis Cardiomyopathy A Case Series
por: Cuddy, Sarah, et al.
Publicado: (2020)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Treatment of acquired transthyretin amyloidosis in domino liver transplantation
por: Tsamis, Konstantinos I., et al.
Publicado: (2022)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Evolving landscape in the management of transthyretin amyloidosis
por: Hawkins, Philip N., et al.
Publicado: (2015)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
por: Gertz, Morie, et al.
Publicado: (2020)

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
por: Obici, Laura, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis
por: Tomoaia, Raluca, et al.
Publicado: (2021)

The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis
por: Driggin, Elissa, et al.
Publicado: (2019)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022)

Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient
por: McColgan, P., et al.
Publicado: (2014)

Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
por: Bandera, Francesco, et al.
Publicado: (2022)

Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis
por: Cheng, Richard K., et al.
Publicado: (2021)

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
por: Mathew, Veena, et al.
Publicado: (2019)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis
por: Giblin, Gerard T, et al.
Publicado: (2022)

Hereditary transthyretine amyloidosis in Slovenia
por: Zidar, Janez
Publicado: (2015)

Multidisciplinary Approaches for Transthyretin Amyloidosis
por: Koike, Haruki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fadj95ac38kp6c81khian1lvsr